Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

AIMS/HYPOTHESIS: Additional safe and effective therapies for type 2 diabetes are needed, especially ones that do not cause weight gain and have a low risk of hypoglycaemia. The present study evaluated albiglutide as monotherapy. METHODS: In this placebo-controlled study, 309 patients (aged ≥18 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Nauck, Michael A., Stewart, Murray W., Perkins, Christopher, Jones-Leone, Angela, Yang, Fred, Perry, Caroline, Reinhardt, Rickey R., Rendell, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705137/
https://www.ncbi.nlm.nih.gov/pubmed/26577795
http://dx.doi.org/10.1007/s00125-015-3795-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705137/
https://www.ncbi.nlm.nih.gov/pubmed/26577795
http://dx.doi.org/10.1007/s00125-015-3795-1

Ejemplares similares